Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals

Set Alert for Deals

Beximco And Mylan Strike Biosimilars Deal

Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.

Deals Biosimilars

Seretide Settlement Lifts Glenmark In Europe

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

Deals Sales & Earnings

Genix Acquires 30 Ophthalmic Dossiers In Canada

Canadian firm Genix has acquired 30 ophthalmic generic dossiers from Canagen. Genix expects to begin commercialization from 2022.

Deals Generic Drugs

Strides Acquires 18 ANDAs From Pharmaceutics

Strides has acquired 18 ANDAs from Pharmaceutics International, as well as exclusive marketing rights to a levothyroxine sodium candidate. Through this agreement, the Indian company plans to expand its niche offerings.

Deals Generic Drugs

The Factory Floor: Biocon, Indoco, Strides And Lupin Line Up For Inspection

Biocon Pharma’s solid-dosage plant has received FDA inspection approval but its parent company was not so lucky, with one of its sites getting hit with five observations. Indoco, Strides, and Lupin were also in the regulatory spotlight while MedPharm has moved into a new, expanded facility and Coripharma has signed a packaging deal with Stada.

Manufacturing Compliance

Dr Reddy’s Snaps Up Wockhardt’s Branded Generics Business

Financially stretched Wockhardt sells select branded generic business to Dr Reddy’s for $260m, bringing the curtains down on a much anticipated transaction.

Deals India
See All
UsernamePublicRestriction

Register